How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

801 results for

Lidocaine Patch

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

681. Symptom Management After Breast Cancer Surgery

Study Details Study Description Go to Brief Summary: This trial is part of a larger, longitudinal study of symptoms that occur in the breast surgical scar area and/or ipsilateral arm following breast cancer surgery. Women who develop pain in the breast scar area or ipsilateral arm will be randomized to a placebo patch or a lidocaine patch that they will wear on a daily basis for 12 weeks. We hypothesize that women who wear the lidocaine patch will report a decrease in pain and decreased interference (...) -Blind, Placebo-Controlled Trial (RDBPCT) of the Effectiveness of the Lidocaine Patch in the Management of Neuropathic Pain After Breast Cancer Surgery Study Start Date : September 2003 Actual Primary Completion Date : December 2007 Actual Study Completion Date : December 2007 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Lidocaine Patch Drug: lidocaine patch 5

2008 Clinical Trials

682. Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

within past year or prior chronic substance abuse (including alcoholism) judged likely to recur during study period by investigator Recent use (within 21 days preceding Day 0) of any topically applied pain medication, such as non-steroidal anti-inflammatory drugs, menthol, methyl salicylate, local anesthetics including Lidoderm® (lidocaine patch 5%), steroids or capsaicin products on painful areas Started or stopped treatment with one or more neurotoxic antiretroviral agents (ie, didanosine [ddI (...) Study Details Study Description Go to Brief Summary: The purpose of the study was to assess the efficacy and safety of NGX-4010 applied for 30 or 60 minutes for the treatment of painful HIV-associated neuropathy. Condition or disease Intervention/treatment Phase Pain HIV Infections Peripheral Nervous System Diseases Drug: NGX-4010, 8% capsaicin patch Drug: 0.04% capsaicin patch Phase 3 Detailed Description: Study C119 was a multicenter, randomized, double-blind, controlled evaluation of the efficacy

2006 Clinical Trials

683. Study of NGX-4010 for the Treatment of Postherpetic Neuralgia

by Investigator. Recent use (within 21 days preceding the Study Patch Application Visit [Day 0]) of any topically applied pain medication, such as non-steroidal anti-inflammatory drugs, menthol, methyl salicylate, local anesthetics including Lidoderm (lidocaine patch 5%), steroids or capsaicin products on the painful areas. Participation in a previous NeurogesX clinical trial in which subject received NGX-4010 (either blinded or open-label study treatment). Current use of any investigational agent, or Class 1 (...) pain from PHN, with average numeric pain rating scale (NPRS) scores during screening of 3 to 9 (inclusive). Painful areas of up to 1000 square centimeters will be treated during a single treatment administration in this study. Subjects will be randomly assigned to receive active NGX-4010 patches or low-concentration control patches that are identical in appearance, according to a 1:1 allocation scheme. Subjects may be on stable chronic oral pain medication regimens, but currently will not be using

2006 Clinical Trials

684. Trial Comparing Intravesical Cocktail With Intravesical Dimethyl Sulfoxide (DMSO) in Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC)

Comparator: DMSO Intravesical installation Drug: dimethyl sulfoxide intravesical installation 50 ml Experimental: Cocktail Drug: IC Cocktail Heparin 10,000 units Gentamicin 80 mg Hydrocortisone sodium succinate (Solucortef) 100 mg Lidocaine hydrochloride 1% 10 ml Sodium Bicarbonate 8.4% 5 ml Outcome Measures Go to Primary Outcome Measures : reduction of frequency of micturition [ Time Frame: 16 weeks ] Secondary Outcome Measures : reduction in pain [ Time Frame: 16 weeks ] overall improvement of symptoms (...) by the study participants and/or their partners include abstinence, birth control pills or patches, diaphragm with spermicide, intrauterine device (IUD), condom and vaginal spermicide, surgical sterilization, vasectomy, or progestin implants or injections. Failure of other treatments for PBS/IC like pentosan polysulfate (failure is defined as a score of +1 [slightly improved] or less on a global assessment response [GRA] 23 question to previous therapy) Exclusion Criteria: Participants who have undergone

2006 Clinical Trials

685. Effect of NGX-4010 on ENFD and Sensory Function

nerve fiber (ENF) regeneration and normalization of peripheral sensory nerve function over time in normal healthy volunteers following a 60 minute application of Capsaicin Dermal Patch (NGX 4010; capsaicin 640 mcg/cm2) as compared to comparable untreated skin areas (control).The objectives of this study are: 1) To assess the difference between patch-treated and comparable untreated skin areas (control) in ENFD as quantified by PGP 9.5 immunohistochemical staining of skin biopsy samples obtained at 1 (...) , 12 and 24 weeks following a 60 minute application; 2) To assess the difference between patch-treated and comparable untreated skin areas (control) for thermal detection thresholds as assessed by QST at 1, 12 and 24 weeks following a 60 minute application; and, 3) To assess the difference between patch-treated and comparable untreated skin areas (control) in mechanical (sharp pain) sensation and tactile threshold at 1, 12 and 24 weeks following a 60 minute application. Condition or disease

2005 Clinical Trials

686. Lamictal in the Treatment of Post-Herpetic Neuralgia

significant abnormal lab values, Known drug allergy to Lamictal, Patients on Fibrates (Tricor and Lopid), History of major psychiatric disturbance and substance abuse. Valproate due to increase chances of severe rash, Lidocaine Patch, Use of hormonal contraceptives (birth control pills, patch, ring, injection) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information

2006 Clinical Trials

687. Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain

Posted : May 7, 2004 Last Update Posted : January 11, 2008 Sponsor: NeurogesX Information provided by: NeurogesX Study Details Study Description Go to Brief Summary: This study is a randomized, open-label multi-center evaluation of the tolerability of treatment with NGX-4010 in conjunction with pre-patch topical application of one of three 4% lidocaine-based local anesthetic products. Eligible subjects will have moderate to severe neuropathic pain secondary to painful diabetic neuropathy (PDN (...) ), postherpetic neuralgia (PHN) or HIV-associated neuropathy (HIV-AN), with average numeric pain rating scale (NPRS) scores during screening of 3 to 8 (inclusive). Condition or disease Intervention/treatment Phase Herpes Zoster Neuralgia Pain HIV Infections Peripheral Nervous System Diseases Diabetic Neuropathies Diabetes Mellitus Polyneuropathies Drug: Capsaicin Dermal Patch Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Allocation: Randomized

2004 Clinical Trials

688. A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy.

of peripheral polyneuropathy pain, and anticonvulsant agents within 2 weeks prior to visit 1 or during the study; Discontinued treatment with antidepressants < 4 weeks prior to visit 1; Current use or use within 2 weeks prior to visit 1 of topical steroids specifically for the treatment of peripheral neuropathy pain; Current use or use within 2 weeks prior to visit 1 of lidocaine patches as a therapy for peripheral neuropathy pain, regardless of frequency or duration of use; History of hormone replacement

2005 Clinical Trials

689. Study of NGX-4010 for the Treatment of Postherpetic Neuralgia

within the past year, or prior chronic substance abuse (including alcoholism) judged likely to recur during the study period by Investigator. Recent use (within 21 days preceding the Study Patch Application Visit [Day 0]) of any topically applied pain medication, such as non-steroidal anti-inflammatory drugs, menthol, methyl salicylate, local anesthetics including Lidoderm (lidocaine patch 5%), steroids or capsaicin products on the painful areas. Participation in a previous NeurogesX clinical trial (...) moderate to severe pain from PHN, with average NPRS scores during screening of 3 to 9 (inclusive). Painful areas of up to 1000 square centimeters will be treated during a single treatment administration in this study. Subjects will be randomly assigned to receive active NGX-4010 patches or low-concentration control patches that are identical in appearance, according to a 1:1 allocation scheme. Subjects may be on stable chronic oral pain medication regimens, but currently will not be using any topical

2005 Clinical Trials

691. Study of Three Capsaicin Dermal Liquid Formulations on Epidermal Nerve Fiber Immunostaining and Sensory Function

, hypothyroidism, asthma or any form of peripheral or central nervous system disease. Use of any systemic medications that interact with the peripheral nervous system, including beta adrenergic blockers, alpha adrenergic blockers, anticonvulsant drugs, antidepressant drugs or opioids within 30 days prior to the Application Visit (Day 0). Use of any topically-applied product including prescription or over the-counter (OTC) analgesic creams/lotions/patches, non steroidal anti-inflammatory drugs, counterirritants (...) and/or self-report. History or current substance abuse including alcoholism/alcohol abuse, as judged by the investigator. Positive test result on the urine drug screen for opioids, cannabis, phencyclidine (PCP), cocaine and amphetamines performed at the Screening Visit. History of hypersensitivity to capsaicin (i.e., chili peppers or OTC capsaicin products), local anesthetics (including lidocaine), adhesives or any other components (see Table 2) of the formulations. Contacts and Locations Go

2007 Clinical Trials

692. Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).

without at least moderate improvement, as judged by the study doctor: antiepileptic drugs, tricyclic antidepressants, serotonin norepinephrine reuptake inhibitors (SNRIs), opioid analgesics, or lidocaine patch currently taking tricyclic antidepressants, Coumadin (warfarin), or continued treatment with an antiepileptic drug for any indication, Note: If taking these medications, to be eligible for the study, they must be tapered and discontinued Prior neurolytic treatment (destruction of nerves

2007 Clinical Trials

693. Metabolism and Thyroid Hormone Changes During Exposure to Cold Temperatures

physical movements. Continuous temperature monitor: Subjects swallow a small capsule that transmits internal body temperature via miniature, wireless sensors. Adhesive patches placed on the skin monitor external body temperature. Blood and urine collections: Subjects collect all of their urine during the 12 hours they are in the metabolic room. Blood samples are taken at specified intervals through a catheter that has been placed in a vein. Microdialysis: A small needle is placed into fat tissue just (...) of antiplatelet or anticoagulants Allergy to lidocaine Pregnancy/breastfeeding/hormonal contraception and childbirth within the last 24 months Perimenopausal (as self-described within two years from onset of amenorrhea or current complaints of hot flashes) Current smoker or user of tobacco products Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided

2007 Clinical Trials

694. Safety Study of Oral BTA9881 to Treat RSV Infection

subjects must be surgically sterile or post-menopausal (defined as at least two years post cessation of menses and/or follicle-stimulating hormone (FSH) >18 mIU/mL and serum oestradiol <110 pmol/L), or must agree to use two forms of the following contraception: oral contraceptives, or other forms of hormonal birth control including hormonal vaginal rings or transdermal patches, intra-uterine devices, condoms, and spermicide during the time interval between dosing until three months after dosing. Female (...) to dosing. Unwillingness or inability to provide Informed Consent or to participate satisfactorily for the entire clinical trial period. Subjects who smoke or have been non-smokers for less than 3 months prior to dosing. Subjects who were previously enrolled in this clinical trial. Poor veins, or fear of venipuncture or sight of blood, or known allergy or hypersensitivity to lidocaine. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you

2007 Clinical Trials

695. Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

., carbamazepine, phenytoin, valproic acid, gabapentin, lamotrigine, topical lidocaine patch or gel, capsaicin cream, or amifostine)> - Patients treated with any of these agents for peripheral neuropathy for ≤ 1 week during the past 30 days are eligible provided they are no longer taking the agent> More than 5 years since prior percutaneous transluminal coronary angioplasty or coronary artery bypass graft> - Prior heart valve replacement surgery allowed provided patient has fully recovered from the surgery

2007 Clinical Trials

696. An Effectiveness and Safety Study With RWJ-333369 (Carisbamate) for the Study of Postherpetic Neuralgia (PHN).

, or lidocaine patch currently taking tricyclic antidepressants, Coumadin (warfarin), or continued treatment with an antiepileptic drug for any indication, Note: If taking these medications, to be eligible for the study, they must be tapered and discontinued past neurolytic treatment (destruction of nerves by the application of chemicals, heat or cold, neurosurgery, intrathecal pumps, or spinal cord stimulators for PHN pain currently using herbal topical creams or ointments for pain relief within 48 hours

2007 Clinical Trials

697. Effectiveness of Controlled-Release Morphine for Chronic Neuropathic Pain After Spinal Cord Injury

will be able to continue any previously prescribed or non-prescribed (over-the-counter) non-opioid medication that has been taken on a regular basis, without dose change, for at least three weeks prior to study entry. These medications may include but are not limited to the analgesics: acetaminophen and any non-steroidal anti-inflammatory drugs; local anesthetics- topical patches such as the lidocaine patch or otherwise; and adjuvant pain medications of the anti-depressant or anticonvulsant classes

2007 Clinical Trials

698. Pharmacokinetic Study of Syneraâ„¢ in Neonates and Infants

Details Study Description Go to Brief Summary: This study will measure the amount of lidocaine and tetracaine in the blood after a 30 minute application of Synera. Condition or disease Intervention/treatment Phase Pain Drug: lidocaine 70mg and tetracaine 70mg topical patch Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 11 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose (...) : Basic Science Official Title: A Pharmacokinetic Study of Synera™ (Lidocaine 70 mg and Tetracaine 70 mg Topical Patch) to Evaluate the Systemic Exposure to Lidocaine and Tetracaine in Neonates and Infants Study Start Date : September 2008 Estimated Primary Completion Date : April 2013 Estimated Study Completion Date : April 2013 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Intervention Details: Drug: lidocaine 70mg and tetracaine 70mg topical

2008 Clinical Trials

699. Fractional Resurfacing Device for Treatment of Acne Scarring

of keloid formation (raised and thickened scars), atrophic dermatitis (extreme skin irritation or itchiness) or immunologic abnormalities such as vitiligo (white patches of skin due to loss of pigment) Have immunocompromised status (inability to resist infection, etc.) Have been treated with lasers, chemical procedures, or other cosmetic procedures on the area to be treated within 6 months of enrollment Have taken Accutane within 12 months of enrollment Are allergic to lidocaine (skin numbing agent

2007 Clinical Trials

700. Syneraâ„¢ for Epidural Needle Insertion

that the analgesic effect of Synera™ analgesic patch would be superior to traditional infiltration with lidocaine for pain of epidural needle insertion in laboring parturients. Condition or disease Intervention/treatment Phase Pain Associated With Epidural Needle Insertion Drug: Synera(TM) Other: Placebo patch Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 33 participants Allocation: Randomized Intervention Model: Parallel Assignment (...) Masking: Double (Participant, Care Provider) Primary Purpose: Treatment Official Title: A Randomized, Double-Blind, Controlled Trial of the Synera™ vs. Lidocaine for Epidural Needle Insertion in Laboring Women Study Start Date : February 2007 Actual Study Completion Date : March 2007 Arms and Interventions Go to Arm Intervention/treatment Placebo Comparator: Placebo Other: Placebo patch placebo patch applied 20 minutes prior to epidural Experimental: Synera(TM) Drug: Synera(TM) Synera(TM) patch

2007 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>